j health sci med / jhsm Journal of Health Sciences and Medicine 2636-8579 MediHealth Academy Yayıncılık 10.32322/jhsm.1720074 Clinical Oncology Chemotherapy Klinik Onkoloji Kemoterapi Baş ve boyun kanserinde Sistemik İmmün-İnflamasyon İndeksinin prognostik değeri Prognostic value of Systemic Immune-Inflammation Index in head and neck cancer https://orcid.org/0000-0003-3247-5361 Kavak Engin Eren ANKARA ETLİK ŞEHİR HASTANESİ https://orcid.org/0009-0005-9043-9790 Dilli İsmail ANKARA ETLİK ŞEHİR HASTANESİ https://orcid.org/0009-0009-9712-0896 Bayır Ömer ANKARA ETLİK ŞEHİR HASTANESİ https://orcid.org/0000-0002-2800-878X Demirci Hüseyin ANKARA ETLİK ŞEHİR HASTANESİ https://orcid.org/0000-0001-7909-9100 Özlügedik Samet ANKARA ETLİK ŞEHİR HASTANESİ 09 16 2025 8 5 747 753 06 15 2025 07 14 2025 Copyright © 2018, Journal of Health Sciences and Medicine 2018 Journal of Health Sciences and Medicine

Amaç: Bu çalışmada, baş ve boyun kanseri hastalarında Sistemik İmmün-İnflamasyon İndeksi’nin (SII) prognostik değeri ile hastalıksız sağkalım (DFS) ve genel sağkalım (OS) gibi sağkalım sonuçlarıyla olan ilişkisi değerlendirildi.Yöntem: Baş ve boyun kanseri tanısı almış hastalar retrospektif olarak analiz edildi. SII cut-off değeri olan 796’ya göre hastalar düşük SII (L-SII) ve yüksek SII (H-SII) olmak üzere iki gruba ayrıldı. Gruplar arasında klinik, demografik ve tedaviye ilişkin parametreler karşılaştırıldı. DFS ve OS analizleri için Kaplan-Meier yöntemine dayalı sağkalım analizleri ve Cox regresyonu kullanılarak univaryant ve multivaryant analizler yapıldı.Bulgular: Toplam 184 hastanın yer aldığı çalışmada, yüksek SII grubundaki (≥796) 67 hastada nüks oranı anlamlı olarak daha yüksek bulundu (%43.3 vs. %8.5, p

Aims: This study aimed to evaluate the prognostic value of the Systemic Immune-Inflammation Index (SII) in patients with head and neck cancer and its association with survival outcomes including disease-free survival (DFS) and overall survival (OS).Methods: The patients diagnosed with head and neck cancer were retrospectively analyzed. Patients were stratified into two groups based on the SII cut-off value (796): low SII (L-SII) and high SII (H-SII). Clinical, demographic, and treatment-related parameters were compared between the groups. Kaplan-Meier survival analysis and Cox regression were used for univariate and multivariate analyses of DFS and OS.Results: Of the total number of patients included in the study (n=184), 67 with high SII (≥796) exhibited significantly higher recurrence rates (43.3% vs. 8.5%, p

 Head and neck cancer Systemic Immune-Inflammation Index overall survival progression-free survival disease-free survival Baş ve boyun kanseri Sistemik immün-inflamasyon indeksi Genel sağkalım Progresyonsuz sağkalım Hastalıksız sağkalım Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg. 2010;143(5):650-654. doi:10.1016/j.otohns. 2010.07.020 O-charoenrat P, Pillai G, Patel S, et al. Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol. 2003;39(4):386-390. doi:10.1016/s1368-8375(02)00142-2 Huang SH, O’Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18(7):40. doi:10.1007/s11864-017-0484-y Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11): e493-e503. doi:10.1016/s1470-2045(14)70263-3 Ye M, Huang A, Yuan B, Tan G, Ai J, Liu H. Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma. Eur Arch Oto Rhino Laryngol. 2024;281(4):1971-1989. doi:10.1007/s00405-024-08474-7 Juesas Iglesias L, Sánchez-Canteli M, Pedregal Mallo D, et al. Prognostic value of preoperative inflammatory ratios in early glottic cancer treated with transoral laser surgery. Head Neck. 2024;46(4):819-830. doi:10. 1002/hed.27631 Iwasa YI, Kitoh R, Yokota Y, et al. Post-treatment neutrophil/lymphocyte ratio is a prognostic factor in head and neck cancers treated with nivolumab. Cancer Diagn Prog. 2024;4(2):182-188. doi:10.21873/cdp.10305 Zhang S, Chen Z, Ling J, et al. Nomograms based on the lymphocyte-albumin-neutrophil ratio (LANR) for predicting the prognosis of nasopharyngeal carcinoma patients after definitive radiotherapy. Scientific Reports. 2024;14(1):5388. doi:10.1038/s41598-024-56043-z Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Nat Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124 Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6): 649-655. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245-1251. doi:10.1200/jco.1992.10.8.1245 Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257-263. doi:10.1200/jco.1992.10.2.257 Recondo G, Armand JP, Tellez-Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope. 1991;101(5):494-501. doi: 10.1288/00005537-199105000-00009 Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer. 2004;101(10):2222-2229. doi:10.1002/cncr.20640 Cadoni G, Giraldi L, Petrelli L, et al. Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy. Acta Otorhinolaryngol Italica. 2017;37(6):458-466. doi:10.14639/0392-100x-1246 Marur S, Li S, Cmelak AJ, et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017;35(5):490-497. doi:10.1200/jco.2016.68.3300 An Y, Park HS, Kelly JR, et al. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer. 2017;123(14):2762-2772. doi:10.1002/cncr.30598 Bauer E, Mazul A, Chernock R, et al. Extranodal extension is a strong prognosticator in HPV-positive oropharyngeal squamous cell carcinoma. Laryngoscope. 2020;130(4):939-945. doi:10.1002/lary.28059 Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer. J Nat Cancer Instit. 2015;107(12):djv344. doi:10.1093/jnci/djv344 Hsueh C, Tao L, Zhang M, et al. The prognostic value of preoperative neutrophils, platelets, lymphocytes, monocytes and calculated ratios in patients with laryngeal squamous cell cancer. Oncotarget. 2017;8(36):60514-60527. doi:10.18632/oncotarget.16234 Tham T, Bardash Y, Herman SW, Costantino PD. Neutrophil-to-lymphocyte ratio as a prognostic indicator in head and neck cancer: a systematic review and meta-analysis. Head Neck. 2018;40(11):2546-2557. doi:10.1002/hed.25324 Wei D, Liu J, Ma J. The value of lymphocyte to monocyte ratio in the prognosis of head and neck squamous cell carcinoma: a meta-analysis. PeerJ. 2023;11:e16014. doi:10.7717/peerj.16014 Wang Y, Xu C, Zhang Z. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis. BMC Med. 2023;21(1):486. doi:10.1186/s12916-023-03199-6 Boscolo-Rizzo P, D’Alessandro A, Polesel J, et al. Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study. BMC Cancer. 2022;22(1):243. doi:10.1186/s12885-022-09327-4 Wang YT, Kuo LT, Weng HH, et al. Systemic Immun e-Inflammation Index as a predictor for head and neck cancer prognosis: a meta-analysis. Front Oncol. 2022;12:899518. doi:10.3389/fonc.2022.899518 Zhou S, Yuan H, Wang J, et al. Prognostic value of systemic inflammatory marker in patients with head and neck squamous cell carcinoma undergoing surgical resection. Future Oncol. 2020;16(10):559-571. doi: 10.2217/fon-2020-0010